>b3:=gha:blj?lf:g g:>e:;hd:
TRANSCRIPT
![Page 1: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/1.jpg)
Ј
( )
И т тут по т у о ед - копје
е тет к кл к е т - п , И т ул, у ј
еке - 26, 2014
. - у ј Апо толо к
ту п е е т ј : Ј у ,
![Page 2: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/2.jpg)
![Page 3: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/3.jpg)
![Page 4: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/4.jpg)
![Page 5: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/5.jpg)
ј ј
В ј ќ - њ
Wells criteria score ј testot na D-dimeri
-
in-vivo ѓ њ
ј В ,
, В
, ,
њ
T ,
Ј
![Page 6: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/6.jpg)
WELLS CRITERIA Score
Active cancer (treatment ongoing or within previous 6 months or palliative) 1
Paralysis, paresis or recent plaster immobilisation of the lower extremity
(within 6 weeks)
1
Recent immobilisation for more than 3 days or major surgery within 12
weeks requiring general or regional anaesthesia
1
Localised tenderness along the deep venous system 1
Entire leg swollen 1
Calf swelling (circumference >3cm more than normal side measured 10cm
below tibial tuberosity)
1
Pitting oedema confined to the symptomatic leg 1
Collateral superficial veins (non-varicose) 1
Previously documented DVT 1
Is alternative diagnosis as likely as, or more likely than DVT?
-2
Total Clinical Score
Exclusions
лед е еу те е е л д
упот е о кл к п о е к , ко е п ут , пот е е е опле улт ук:
• од од
• е е о т
• о л ко т еп ј
• дол п ту њ о о
• ет од о В л P.E. *
• те п е т о п ет од В / е о " ок к«.
лт ук: И д е о к ј п е т о ок кл к
е ој т о т В л п к о е о к е ој т о т, о о по т
-д е . Unlikely - л = к е ој т о т В п е ле - , % . -д е е д т е т
п о о т к ед о т, т.е. е т е е улт т ќе клу В . е д е по ек т е улт т те п ед д е по улт ук п л о / од ко те п е т т по т -д е е пот е е улт ук . К ј е т -д е е е пот е о по т о о п ту ње, о е ко пто те пе т т л е ло т. Likely - л по еќе = ок кл к е ој т о т В п е ле - % . -д е е е пот е . е п одол у д ект о о улт ук.
![Page 7: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/7.jpg)
![Page 8: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/8.jpg)
И ј
В јќ В , - , ј ,
, ј ј ј .
Ф
:
- ј (
),
- ,
- Baker- , - .
![Page 9: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/9.jpg)
![Page 10: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/10.jpg)
![Page 11: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/11.jpg)
њ
• ( јќ ), • INR,
• ( њ Clexane)
![Page 12: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/12.jpg)
![Page 13: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/13.jpg)
ј ј <50
, ј , ј
ј
![Page 14: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/14.jpg)
ј
- ј В -
- ј , - .
Н - ј ј њ
ј 7
![Page 15: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/15.jpg)
![Page 16: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/16.jpg)
Renal function Dose Notes
Normal renal function
CrCl > 80mL/min
1.5mg/kg daily
• if >100kg, obese (BMI
>30kg/m2) or cancer,
consider using 1mg/kg bd
• if <45kg
• use actual body weight
• calculate CrCl
Moderate/mild renal
impairment
CrCl 30-80mL/min
1.5mg/kg daily
with careful monitoring (eg
renal function)
•use actual body weight
• calculate CrCl
Severe renal impairment
CrCl <30mL/min
1mg/kg daily
• use actual body weight
• calculate CrCl
Ко Wells score е ≥ ко улт ук е о е д е п ≥ е д LMWH - Clexane
то по о е по у о п еклоп о LMWH ОА де INR д де ≥ 2
![Page 17: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/17.jpg)
Table 1
A) Conditions favoring full anticoagulation for 3 mo (as for proximal DVT)
Previous VTE events
Idiopathic event
Secondary event but with persistently hampered complete mobilization
Event occurring during pregnancy or puerperium
Distal thrombosis involving the popliteal trifurcation
Thrombosis involving >1 calf vein
Distal thrombosis present in both legs
Active cancer or chemotherapy
Presence of predisposing diseases (eg, inflammatory bowel diseases)
Known thrombophilic alterations
B) Conditions favoring shorter anticoagulation
First thrombotic event, if:
- secondary to surgery or to other removable risk factors (eg, plasters, immobilization, trauma, long trip)
- event occurring during contraceptive or replacement hormonal therapy (provided the therapy has been interrupted)
- with subsequent full mobilization
- no difference between muscular or tibial-peroneal veins EBM Guidelines
![Page 18: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/18.jpg)
В е ет ење т ко ул т те п ј
И дикација Вре етраење а терапијата
еп од т о о т то е
л од к п ед по к
кто у ј , т у , о т
к е ет, те п ј о е т о е
3- е е
еп од т о о е
п ед по к кто
Н ј лку е е
еп од т о о к ј п е т о
к о , к д ол п к т тел , ко ко ул о у у њ , о о оте кто V Ле де л
ут ј п от о к е
е е до до от о
о то у к т о о е
п ед по к кто л пој о
оод о о пе ко ул л о т к т
о от о В ок к а DVT = 3+
С еден к а DVT = 1-2
Н ок к а DVT = < 1 EBM ј
![Page 19: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/19.jpg)
проце ет р к од по тору ање о текот а пр ата од а а а те е % 8% а е те
![Page 20: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/20.jpg)
Ш ц
, ј
ј ( ј , , , ...)
ј , ј
, ј
( ј )
ѓ
ј ј
ј , ј , ј ...
А ц ј -
![Page 21: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/21.jpg)
–
anti – Xa UH LMWHs,
( 15 ,
)
В ,
, ј 6 12 , ј
њ 2 (
50%)
ј
ј
, ,
њ , ј
ј .
![Page 22: >B3:=GHA:BLJ?LF:G G:>E:;HD:](https://reader035.vdocuments.pub/reader035/viewer/2022070903/5f6750c7fdf026718b110eed/html5/thumbnails/22.jpg)